A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder
The DOI matches its Crossref record.
Abstract
Objective Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD). Method Treatment-resistant depression was defined as a documented history of current-episode antidepressant failure plus a prospective failure on fluoxetine. Following an 8-week fluoxetine lead-in, 605 nonresponders with DSM-IV major depressive disorder were randomly assigned to olanzapine/fluoxetine combination, olanzapine, or fluoxetine. The primary outcome measure was baseline-to-endpoint mean change on the Montgomery-Asberg Depression Rating Scale (MADRS). The study was conducted from April 2002 to May 2005. Results After 8 weeks of double-blind treatment, Study 1 revealed no statistically significant therapy differences in MADRS mean change (olanzapine/fluoxetine combination: -11.0, fluoxetine: -9.4, olanzapine: -10.5). In Study 2, olanzapine/fluoxetine combination demonstrated significantly greater MADRS improvement (-14.5) than fluoxetine (-8.6, p Conclusion Patients with TRD (defined as treatment failure on 2 antidepressants) taking olanzapine/fluoxetine combination demonstrated significantly greater improvement in depressive symptoms than patients taking olanzapine or fluoxetine in 1 of 2 studies and in the pooled analysis. When considered within the context of all available evidence, olanzapine/fluoxetine combination is an efficacious therapy for patients with TRD. Clinical trials registr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The response and remission rates seen in the antidepressant plus placebo arm were higher than those reported in the Sequenced Treatment Alternatives to Relieve Depression trial for step 3 (response rate, 16.8%; remission rate, 13.7%) and in the olanzapine-fluoxetine study (33)”
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 228
A review of quetiapine in combination with antidepressant therapy in patients with depression
Daly, E., & Trivedi, M. H. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1862 · Cited by 29
Nelson, J. C., & Papakostas, G. I. (2010) · Focus · doi:10.1176/foc.8.4.foc570 · Cited by 23
Addressing sympathetic overactivity in major depressive disorder
Hausberg, M., Hillebrand, U., & Kisters, K. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282ef9819 · Cited by 27
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
Dodd, S., & Berk, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1299 · Cited by 22
Bobo, W. V., & Shelton, R. C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5819 · Cited by 27
D, M. F. M., Wisniewski, S. R., Thase, M. E., Baker, R. A., Tran, Q.-V., Pikalov, A., Yang, H., Marcus, R. N., & Berman, R. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ac9b0b · Cited by 23
Self-citationBobo, W. V., & Shelton, R. C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.44 · Cited by 24
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2016) · Focus · doi:10.1176/appi.focus.140202 · Cited by 20
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Prevalence and correlates of depression with atypical symptoms in Hong Kong
Lee, S., Ng, K. L., & Tsang, A. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903279895 · Cited by 19
Use of atypical antipsychotics for treatment-resistant major depressive disorder
Papakostas, G. I., & Shelton, R. C. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0077-3 · Cited by 26
Nelson, J. C., Rahman, Z. U., Laubmeier, K. K., Eudicone, J. M., McQuade, R. D., Berman, R., Marcus, R. N., Baker, R. A., & Sheehan, J. J. (2014) · CNS Spectrums · doi:10.1017/s109285291300103x · Cited by 20
Treutlein, J., Strohmaier, J., Frank, J., Witt, S. H., Rietschel, L., Forstner, A. J., Lang, M., Degenhardt, F., Dukal, H., Herms, S., et al. (2017) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000149 · Cited by 18
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
de Bartolomeis, A., Avvisati, L., Iasevoli, F., & Tomasetti, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.034 · Cited by 18
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Herrero, R. D., Elices, M., Feeney, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0096 · Cited by 20
Self-citationTargeting Treatment-Resistant Depression
Mathys, M. L., & Mitchell, B. G. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426972 · Cited by 22
Synthesis of 2,4-dihydroxychalcone Derivatives as Potential Antidepressant Effect
Guan, L., Zhao, D., Chang, Y., Wen, Z., Tang, L.-M., & Huang, F.-F. (2013) · Drug Research · doi:10.1055/s-0032-1333229 · Cited by 17
Synthesis and antidepressant-like action of N-(2-hydroxyethyl) cinnamamide derivatives in mice
Deng, X., Wu, D., Wei, C., & Quan, Z. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9470-7 · Cited by 17
Treatment-Resistant Depression: An Update on Diagnosis and Management
Janicak, P. G., & Dowd, S. M. (2009) · Psychopharm Review · doi:10.1097/01.idt.0000350191.07142.ef · Cited by 17
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients
Houston, J., Fijal, B. A., Heinloth, A. N., & Adams, D. H. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.06.014 · Cited by 17
Guan, L., Tang, L.-M., Pan, C.-Y., Zhao, S.-L., & Wang, S. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1224-8 · Cited by 16
Weiller, E., Weiss, C., Watling, C. P., Edge, C., Hobart, M., Eriksson, H., & D, M. F. M. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s146840 · Cited by 18
Etiévant, A. (2010) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523801003010001 · Cited by 19
Aftab, A., & Gao, K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1354849 · Cited by 15
Chen, S.-J., Hsiao, Y.-L., Shen, T.-W., & Chen, S. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f6c7f · Cited by 14
Taneja, C., Papakostas, G. I., Jing, Y., Baker, R. A., Forbes, R. A., & Oster, G. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q326 · Cited by 13
Desai, U. S., Kirson, N. Y., Guglielmo, A., Le, H. H., Spittle, T., Tseng-Tham, J., Shawi, M., & Sheehan, J. J. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0276 · Cited by 15
EFFECTS OF DIFFERENT PSYCHOTROPIC AGENTS ON THE CENTRAL NERVE GROWTH FACTOR PROTEIN
Hassanzadeh, P., & Hassanzadeh, A. (2010) · Iranian journal of basic medical sciences. · doi:10.22038/ijbms.2010.5064 · Cited by 12
New dual ligands for the D2 and 5-HT1A receptors from the group of 1,8-naphthyl derivatives of LCAP
Zaręba, P., Jaśkowska, J., Śliwa, P., & Satała, G. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.029 · Cited by 13
Morita, M., & Nakayama, K. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02191.x · Cited by 12
Therapeutic potential of new second generation antipsychotics for major depressive disorder
McElroy, S. L., Guerdjikova, A. I., Mori, N. N., & Keck, P. E. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.538048 · Cited by 15
The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression
Blumberger, D. M., Mulsant, B. H., Kanellopoulos, D., Whyte, E. M., Rothschild, A. J., Flint, A. J., & Meyers, B. S. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828bf059 · Cited by 11
Şaylan, M., Treur, M., Postema, R., Dılbaz, N., SAVAS, H. A., Heeg, B. M. S., & Drost, P. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.004 · Cited by 13
Switching Antidepressants vs. Conventional Augmentation Strategies
Papakostas, G. I. (2009) · CNS Spectrums · doi:10.1017/s1092852900003527 · Cited by 11
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
Sussman, M., Yu, J., Kamat, S., Hartry, A., Legacy, S. N., Duffy, R. A., & Aigbogun, M. S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.006 · Cited by 11
Blatt, S. J., & Luyten, P. (2009) · Neuropsychoanalysis · doi:10.1080/15294145.2009.10773594 · Cited by 14
P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats
Xu, Y., Lu, J., Yao, B., Zhang, Y., Huang, S., Liu, J., Zhang, Y., Guo, Y., & Wang, X. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115735 · Cited by 9
Kitaichi, Y., Inoue, T., Izumi, T., Nakagawa, S., Tanaka, T., Masui, T., & Koyama, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.019 · Cited by 11
McIntyre, R. S., Stahl, S. M., Shim, S. R., Pompili, M., Goldberg, J. F., Correll, C. U., Kwan, A. T. H., Dri, C. E., Xu, H., Vinberg, M., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0658 · Cited by 12
Seo, R. J., MacPherson, H., & Young, A. H. (2010) · Pharmaceuticals · doi:10.3390/ph3123522 · Cited by 10
Wang, J., Li, W., Li, M., Wu, H.-B., & Qiu, Z.-K. (2023) · Medicine · doi:10.1097/md.0000000000034670 · Cited by 12
Current evidence for aripiprazole as augmentation therapy in major depressive disorder
Khan, A. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1435 · Cited by 10
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 9
The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression
Kasper, S. F., & Akimova, E. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch5 · Cited by 9
Fjukstad, K. K., Engum, A., Lydersen, S., Dieset, I., Steen, N. E., Andreassen, O. A., & Spigset, O. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.04.001 · Cited by 8
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Weisler, R. H., McIntyre, R. S., & Bauer, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.846519 · Cited by 8
Fixed dose-combination products in psychiatry: Systematic review and meta-analysis
Farooq, S., & Singh, S. P. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114541016 · Cited by 7
Examining the Evidence on Augmentation with Atypical Antipsychotics
Papakostas, G. I. (2007) · CNS Spectrums · doi:10.1017/s1092852900016023 · Cited by 6
Contemporary Concepts in the Pharmacotherapy of Depression in Older People
Rojas‐Fernandez, C. H., & Mikhail, M. (2012) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3821/145.3.cpj128 · Cited by 6
Koutrouli, I. R. A., Mazochová, K., & Horsley, R. R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177604 · Cited by 8
Drug safety evaluation of olanzapine/fluoxetine combination
Cristancho, M. A., & Thase, M. E. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.933804 · Cited by 7
Self-citationPartial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents
Etiévant, A., Betry, C., & Haddjeri, N. (2010) · The Open Neuropsychopharmacology Journal · Cited by 6
Antidepressant-like Effect of a Chalcone Compound, DHIPC and Its Possible Mechanism.
Zhao, D., Wang, Y., Zheng, L., Liu, B., & Guan, L. (2018) · Europe PMC (PubMed Central) · Cited by 6
Doumy, O., Bennabi, D., el-Hage, W., Allaïli, N., Bation, R., Bellivier, F., Holtzmann, J., Bubrovszky, M., Camus, V., Charpeaud, T., et al. (2016) · Presse medicale · doi:10.1016/j.lpm.2016.02.004 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Degenhardt, E. K., Jamal, H. H., Tormey, S., & Case, M. G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182196e64 · Cited by 6
Self-citationBaldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_3 · Cited by 9
Ali, E., Latif, F., Mashkoor, Y., Sheikh, A., Iqbal, A., Owais, R., Ahmed, J., Naveed, S., Moeed, A., Ullah, I., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104005 · Cited by 5
Xu, P., Wu, S., Zhao, J., Liu, J., & Zhang, X. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07197-1 · Cited by 5
Uzungil, V., Luza, S., Opazo, C., Mees, I., Li, S., Ang, C., Williamson, N. A., Bush, A. I., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109837 · Cited by 3
Fasipe, O. J. (2019) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_110_18 · Cited by 7
Antai-Otong, D. (2007) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2007.00123.x · Cited by 5
Leelahanaj, T. (2010) · PubMed · Cited by 5
Ye, J., Liu, K., Zhou, X., Gu, J.-M., & Hu, X.-R. (2018) · Crystallography Reports · doi:10.1134/s1063774518060147 · Cited by 3
Tamayo, J. M., Ruiz, Y. P., & Ruíz, I. (2015) · Archivos de Neurociencias · doi:10.31157/an.v20i1.66 · Cited by 3
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 5
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
A case of treatment-resistant depression in an older adult and a discussion of treatment options
Pope, E., Muthukrishnan, S., Phillips, J., & Phillips, S. M. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.105 · Cited by 3
Wang, S., Anderson, I. M., Mitchell, D., Johnson, S. J., & Shiozawa, A. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s181718 · Cited by 4
Electroconvulsive therapy or antipsychotic drugs (or benzodiazepines for catatonia)
Swartz, C. M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511576393.024 · Cited by 2
Neuroprotection in Bipolar Depression
Aiken, C. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_15 · Cited by 2
Antipsicóticos atípicos na depressão refratária
Sarin, L. M., & Porto, J. A. D. (2009) · Jornal Brasileiro de Psiquiatria · doi:10.1590/s0047-20852009000200001 · Cited by 11
Rasasingham, R. (2014) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2014.43024 · Cited by 2
Effects of psychotropic drugs on nerve growth factor protein levels in the rat brain
Hassanzadeh, P., & Hassanzadeh, A. (2009) · Cited by 3
Le, G. H., Wong, S., Johnson, D. E., Orsini, D. K., Zheng, Y. J., Teopiz, K. M., Dri, C. E., Rosenblat, J. D., & McIntyre, R. S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70344 · Cited by 1
Moazenzadeh, M., Mirzazadeh, A., & Salari, P. (2008) · ARYA atherosclerosis · Cited by 1
Clinical models for managing Bipolar II disorder: model 2
Ketter, T. A., & Wang, P. W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003315.019 · Cited by 1
Tedaviye Dirençli Depresyonlarda Yeni Antipsikotiklerin Yeri
Çetin, M. (2010) · Cited by 3
The Role of Atypical Antipsychotic Therapy for Patients with Treatment- Resistant Bipolar Depression
Shah, A. S. (2014) · African Journal of Psychiatry · doi:10.4172/1994-8220.1000150 · Cited by 1
Fasipe, O. J., & Ogunboye, I. (2024) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqae017 · Cited by 9
Prevalence and Impact of Hypomania Among Night-Shift Healthcare Professionals
Akhtar, A. W., Khan, A. K., Azeem, M. K., Shahbaz, A., Khalil, M., & Munawar, A. (2024) · Indus journal of bioscience research. · doi:10.70749/ijbr.v2i02.372 · Cited by 1
Easing the Burden of Treatment-Resistant Depression
Fava, M., Nelson, J. C., Thase, M. E., & Trivedi, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.bm8017ah1c · Cited by 2
Self-citationAdjunctive quetiapine may help depression comorbid with pervasive developmental disorders
Tufan, A. E., & KUTLU, H. T. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.09.009 · Cited by 1
Insulin resistance in major depressive disorder and the effects of psychotropic medications
Mason, J. S., Kenna, H. A., & Rasgon, N. (2012) · Clinical Practice · doi:10.2217/cpr.12.46 · Cited by 2
Major Depresif Bozukluk Tedavisinde Yetersiz Yanıtın Yönetimi ve Yeni Tedavi Seçenekleri
Karamustafalıoğlu, O., & Yavuz, B. G. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2011.11790745 · Cited by 4
Kato, H., Koizumi, T., Takeuchi, H., Tani, H., Mimura, M., & Uchida, H. (2020) · Pharmacopsychiatry · doi:10.1055/a-1330-8587 · Cited by 1
Combined treatments for major depression
Joffe, R. T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1379 · Cited by 1
Tamayo, J. M., Rosales-Barrera, J. I., Villaseñor-Bayardo, S. J., & Rojas-Malpica, C. (2011) · Salud Mental · Cited by 5
Lazowski, L. (2009) · QSpace (Queen's University Library) · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Antipsychotiques de seconde génération dans la dépression résistante : données cliniques
Mouchabac, S. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-73727-5.00003-9
Ist die Klassifikation der Bipolarität von Akiskal in die Praxis umsetzbar
Severus, E., Riedel, M., & Hj, M. (2009) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., & Bauer, M. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50012-5
The Nature and Treatment of Therapy-Resistant Depression
Kennedy, S. H., Rizvi, S. J., & Giacobbe, P. (2010) · Modern trends in psychiatry · doi:10.1159/000319516 · Cited by 1
La depressione maggiore resistente: update delle strategie di trattamento farmacologico
Bellantuono, C. (2011) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2011.08.001
Use of second generation antipsychotics for treatment-resistant major depressive disorder
Waite, R. (2014) · Mental Health Clinician · doi:10.9740/mhc.n207192 · Cited by 1
Aghadavoudi, O., Sajedi, P., & Saryazdi, H. (2007) · ARYA atherosclerosis
Shah, A. S. (2015) · International Journal of Emergency Mental Health and Human Resilience · doi:10.4172/1522-4821.1000198
Metadata
- Authors
- Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S.
- Affiliations
- University of Pittsburgh (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-02-15
- Volume
- 68
- Issue
- 02
- Pages
- 224-236
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2125094332
- Cited by
- 228
- References
- 0
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 4 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 15 · 2013: 24 · 2012: 8
- FWCI
- 18.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- treatment-resistant depression, major depressive disorder, olanzapine, fluoxetine, olanzapine-fluoxetine combination, atypical antipsychotics, antidepressant non-response, remission rate, cholesterol, weight gain, hyperglycemia, adverse events, outpatients, Montgomery-Asberg Depression Rating Scale, antidepressant efficacy comparison, antipsychotic augmentation, adjunctive therapy
- MeSH terms
- Olanzapine, Adolescent, Adult, Aged, Benzodiazepines, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Antipsychotic Agents, Treatment Failure, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.